Skip to main navigation
Link to Sight Sciences Corporate Site
  • Overview
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • News & Events
    • News Releases
    • Investor Calendar
    • Presentations
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Annual Reports and Proxy
  • Corporate Governance
    • Governance Highlights
    • Management
    • Board of Directors
    • Committee Composition
    • ESG
  • Investor Resources
    • Investor FAQs
    • Clinical Publications
    • Email Alerts
    • Contact IR

News Releases

14 Jan '25
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported select
07 Jan '25
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma
The study is the largest to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy. It analyzes real-world data from the American Academy of Ophthalmology IRIS® Registry and demonstrates sustained intraocular pressure reductions and decreased medication dependence MENLO
  • Email Alerts
  • Print Page
  • RSS Feeds

© 2025 Sight Sciences ®. All rights reserved.

Copyright Links

Site Map